1344-P: Persistent ß-Cell Responsiveness in Children at High Risk for Type 1 Diabetes (T1D) Is Associated with Decreased Progression to T1D in the Diabetes Prevention Trial-Type 1 (DPT-1)

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 1344-P
Author(s):  
EMILY K. SIMS ◽  
HEBA M. ISMAIL ◽  
BRANDON M. NATHAN ◽  
JAY M. SOSENKO
Keyword(s):  
Type 1 Diabetes ◽  
High Risk ◽  
Trial Type ◽  
Diabetes Prevention ◽  
Prevention Trial

scholarly journals Slowed Metabolic Decline After 1 Year of Oral Insulin Treatment Among Individuals at High Risk for Type 1 Diabetes in the Diabetes Prevention Trial–Type 1 (DPT-1) and TrialNet Oral Insulin Prevention Trials

Diabetes ◽  
2020 ◽  
Vol 69 (8) ◽  
pp. 1827-1832 ◽  
Author(s):  
Jay M. Sosenko ◽  
Jay S. Skyler ◽  
Kevan C. Herold ◽  
Desmond A. Schatz ◽  
Michael J. Haller ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
High Risk ◽  
Trial Type ◽  
Diabetes Prevention ◽  
Insulin Treatment ◽  
Prevention Trial ◽  
Oral Insulin ◽  
Prevention Trials

scholarly journals Slowed Metabolic Decline after One Year of Oral Insulin Treatment among Individuals at High Risk for Type 1 Diabetes in the Diabetes Prevention Trial-Type 1 and TrialNet Oral Insulin Prevention Trials

2020 ◽  
Author(s):  
Ada Admin ◽  
Jay M. Sosenko ◽  
Jay S. Skyler ◽  
Kevan C. Herold ◽  
Desmond A. Schatz ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Placebo Group ◽  
High Risk ◽  
Trial Type ◽  
Diabetes Prevention ◽  
Prevention Trial ◽  
Oral Insulin ◽  
C Peptide ◽  
Insulin Group

We assessed whether oral insulin slowed metabolic decline after 1 year of treatment in individuals at high risk for type 1 diabetes.<b> </b>Two oral insulin trials that were negative overall with type 1 diabetes as the primary endpoint were analyzed: the Diabetes Prevention Trial-Type 1 (DPT-1) and TrialNet oral insulin trials. Oral glucose tolerance tests at baseline and after 1 year of treatment were analyzed. Among those at high risk [Diabetes Prevention Trial Risk Score (DPTRS)≥6.75], the AUC C-peptide increased significantly from baseline to 1 year in each oral insulin group, whereas AUC glucose increased significantly in each placebo group. At 1 year, AUC C-peptide/AUC glucose was significantly higher (p<0.05) in the oral insulin group than in the placebo group in each trial (p=0.057 with age adjustment in the TrialNet trial; p<0.01 for trials combined with or without age adjustment). For DPTRS<6.75, oral insulin groups did not differ from placebo groups. <a>The findings suggest that 1 year of treatment with oral insulin slows metabolic deterioration in individuals at high risk for type 1 diabetes.</a> Moreover, the findings further suggest that metabolic endpoints can be useful adjuncts to the diagnostic endpoint in assessments of preventive treatments for the disorder.

scholarly journals Slowed Metabolic Decline after One Year of Oral Insulin Treatment among Individuals at High Risk for Type 1 Diabetes in the Diabetes Prevention Trial-Type 1 and TrialNet Oral Insulin Prevention Trials

2020 ◽  
Author(s):  
Ada Admin ◽  
Jay M. Sosenko ◽  
Jay S. Skyler ◽  
Kevan C. Herold ◽  
Desmond A. Schatz ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Placebo Group ◽  
High Risk ◽  
Trial Type ◽  
Diabetes Prevention ◽  
Prevention Trial ◽  
Oral Insulin ◽  
C Peptide ◽  
Insulin Group

We assessed whether oral insulin slowed metabolic decline after 1 year of treatment in individuals at high risk for type 1 diabetes.<b> </b>Two oral insulin trials that were negative overall with type 1 diabetes as the primary endpoint were analyzed: the Diabetes Prevention Trial-Type 1 (DPT-1) and TrialNet oral insulin trials. Oral glucose tolerance tests at baseline and after 1 year of treatment were analyzed. Among those at high risk [Diabetes Prevention Trial Risk Score (DPTRS)≥6.75], the AUC C-peptide increased significantly from baseline to 1 year in each oral insulin group, whereas AUC glucose increased significantly in each placebo group. At 1 year, AUC C-peptide/AUC glucose was significantly higher (p<0.05) in the oral insulin group than in the placebo group in each trial (p=0.057 with age adjustment in the TrialNet trial; p<0.01 for trials combined with or without age adjustment). For DPTRS<6.75, oral insulin groups did not differ from placebo groups. <a>The findings suggest that 1 year of treatment with oral insulin slows metabolic deterioration in individuals at high risk for type 1 diabetes.</a> Moreover, the findings further suggest that metabolic endpoints can be useful adjuncts to the diagnostic endpoint in assessments of preventive treatments for the disorder.

scholarly journals Patterns of Metabolic Progression to Type 1 Diabetes in the Diabetes Prevention Trial-Type 1

Diabetes Care ◽  
2006 ◽  
Vol 29 (3) ◽  
pp. 643-649 ◽  
Author(s):  
J. M. Sosenko ◽  
J. P. Palmer ◽  
C. J. Greenbaum ◽  
J. Mahon ◽  
C. Cowie ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Trial Type ◽  
Diabetes Prevention ◽  
Prevention Trial

scholarly journals Glucose and C-Peptide Changes in the Perionset Period of Type 1 Diabetes in the Diabetes Prevention Trial-Type 1

Diabetes Care ◽  
2008 ◽  
Vol 31 (11) ◽  
pp. 2188-2192 ◽  
Author(s):  
J. M. Sosenko ◽  
J. P. Palmer ◽  
L. Rafkin-Mervis ◽  
J. P. Krischer ◽  
D. Cuthbertson ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Trial Type ◽  
Diabetes Prevention ◽  
Prevention Trial ◽  
C Peptide

scholarly journals A Risk Score for Type 1 Diabetes Derived From Autoantibody-Positive Participants in the Diabetes Prevention Trial-Type 1

Diabetes Care ◽  
2007 ◽  
Vol 31 (3) ◽  
pp. 528-533 ◽  
Author(s):  
J. M. Sosenko ◽  
J. P. Krischer ◽  
J. P. Palmer ◽  
J. Mahon ◽  
C. Cowie ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Risk Score ◽  
Trial Type ◽  
Diabetes Prevention ◽  
Prevention Trial

scholarly journals High frequency of abnormal glucose tolerance in DQA1*0102/DQB1*0602 relatives identified as part of the Diabetes Prevention Trial?Type 1 Diabetes

Diabetologia ◽  
2004 ◽  
Vol 48 (1) ◽  
pp. 68-74 ◽  
Author(s):  
C. J. Greenbaum ◽  
G. Eisenbarth ◽  
M. Atkinson ◽  
L. Yu ◽  
S. Babu ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Glucose Tolerance ◽  
Trial Type ◽  
High Frequency ◽  
Diabetes Prevention ◽  
Prevention Trial ◽  
Abnormal Glucose Tolerance

scholarly journals Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for Improving the Accuracy of the Risk Classification of Type 1 Diabetes

Diabetes Care ◽  
2014 ◽  
Vol 37 (4) ◽  
pp. 979-984 ◽  
Author(s):  
Jay M. Sosenko ◽  
Jay S. Skyler ◽  
Jeffrey Mahon ◽  
Jeffrey P. Krischer ◽  
Carla J. Greenbaum ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Risk Score ◽  
Trial Type ◽  
Diabetes Prevention ◽  
Risk Classification ◽  
Prevention Trial

scholarly journals The Application of the Diabetes Prevention Trial-Type 1 Risk Score for Identifying a Preclinical State of Type 1 Diabetes

Diabetes Care ◽  
2012 ◽  
Vol 35 (7) ◽  
pp. 1552-1555 ◽  
Author(s):  
J. M. Sosenko ◽  
J. S. Skyler ◽  
J. Mahon ◽  
J. P. Krischer ◽  
C. A. Beam ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Risk Score ◽  
Trial Type ◽  
Diabetes Prevention ◽  
Prevention Trial

scholarly journals Pancreatic Islet Autoantibodies as Predictors of Type 1 Diabetes in the Diabetes Prevention Trial-Type 1

Diabetes Care ◽  
2009 ◽  
Vol 32 (12) ◽  
pp. 2269-2274 ◽  
Author(s):  
T. Orban ◽  
J. M. Sosenko ◽  
D. Cuthbertson ◽  
J. P. Krischer ◽  
J. S. Skyler ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Pancreatic Islet ◽  
Trial Type ◽  
Diabetes Prevention ◽  
Prevention Trial ◽  
Islet Autoantibodies
Sign in / Sign up

Export Citation Format

Share Document